Provided by Tiger Fintech (Singapore) Pte. Ltd.

Orchestra BioMed

2.97
+0.440017.39%
Post-market: 3.030.0600+2.02%16:06 EDT
Volume:783.33K
Turnover:2.24M
Market Cap:113.79M
PE:-1.79
High:3.03
Open:2.62
Low:2.58
Close:2.53
Loading ...

Major Shareholder Boosts Investment in Orchestra BioMed Holdings!

TIPRANKS
·
Yesterday

Orchestra BioMed Receives US FDA Approval for Heart Device Trial

MT Newswires Live
·
Yesterday

BRIEF-Orchestra Biomed Receives FDA Approval Of Ide To Initiate U.S. Coronary Pivotal Trial Randomizing First-In-Class Sirolimus-Angioinfusion Balloon, Virtue Sab, Head-To-Head With Paclitaxel-Coated Balloon

Reuters
·
29 Apr

Orchestra Biomed Holdings Inc: Targeting Initiation of Virtue Trial During Second Half of 2025

THOMSON REUTERS
·
29 Apr

Orchestra Biomed Receives FDA Approval of Ide to Initiate U.S. Coronary Pivotal Trial Randomizing First-in-Class Sirolimus-Angioinfusion Balloon, Virtue SAB, Head-to-Head With Paclitaxel-Coated Balloon

THOMSON REUTERS
·
29 Apr

Orchestra BioMed Holdings: Buy Rating Affirmed on Breakthrough Device Designation and Promising AVIM Therapy Developments

TIPRANKS
·
24 Apr

Orchestra BioMed granted breakthrough device designation, says H.C. Wainwright

TIPRANKS
·
24 Apr

Orchestra BioMed Holdings Is Maintained at Buy by Chardan Capital

Dow Jones
·
23 Apr

Orchestra BioMed Says AVIM Therapy Gets US FDA Breakthrough Device Designation

MT Newswires Live
·
22 Apr

Orchestra Biomed Holdings Shares up 9% on FDA's Fast Track Tag for Blood Pressure Therapy

THOMSON REUTERS
·
22 Apr

Orchestra BioMed Shares Rally After FDA Breakthrough Approval for Blood-Pressure Device

Dow Jones
·
22 Apr

BRIEF-Orchestra Biomed Receives FDA Breakthrough Device Designation For Avim Therapy

Reuters
·
22 Apr

Orchestra Biomed Receives FDA Breakthrough Device Designation for Avim Therapy

THOMSON REUTERS
·
22 Apr

Orchestra BioMed Receives FDA Breakthrough Device Designation for AVIM Therapy

GlobeNewswire
·
22 Apr

Orchestra BioMed’s Strategic Advances in Medical Innovations

TIPRANKS
·
08 Apr

Orchestra BioMed Holdings Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
04 Apr

Orchestra Biomed Holdings, Inc. : H.c. Wainwright Cuts Target Price to $12 From $14

THOMSON REUTERS
·
04 Apr

Orchestra BioMed Holdings Full Year 2024 Earnings: Revenues Disappoint

Simply Wall St.
·
02 Apr

Orchestra BioMed Holdings Is Maintained at Buy by Chardan Capital

Dow Jones
·
02 Apr

Orchestra BioMed Reports Full Year 2024 Financial Results and Provides a Fourth Quarter Business Update

GlobeNewswire
·
01 Apr